199 related articles for article (PubMed ID: 32376625)
21. Functional antagonism of rhesus macaque and chimpanzee BST-2 by HIV-1 Vpu is mediated by cytoplasmic domain interactions.
Yoshida T; Koyanagi Y; Strebel K
J Virol; 2013 Dec; 87(24):13825-36. PubMed ID: 24109238
[TBL] [Abstract][Full Text] [Related]
22. The transmembrane domain of HIV-1 Vpu is sufficient to confer anti-tetherin activity to SIVcpz and SIVgor Vpu proteins: cytoplasmic determinants of Vpu function.
Kluge SF; Sauter D; Vogl M; Peeters M; Li Y; Bibollet-Ruche F; Hahn BH; Kirchhoff F
Retrovirology; 2013 Mar; 10():32. PubMed ID: 23514615
[TBL] [Abstract][Full Text] [Related]
23. A cytoplasmic tail determinant in HIV-1 Vpu mediates targeting of tetherin for endosomal degradation and counteracts interferon-induced restriction.
Kueck T; Neil SJ
PLoS Pathog; 2012; 8(3):e1002609. PubMed ID: 22479182
[TBL] [Abstract][Full Text] [Related]
24. HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes.
Iwabu Y; Fujita H; Kinomoto M; Kaneko K; Ishizaka Y; Tanaka Y; Sata T; Tokunaga K
J Biol Chem; 2009 Dec; 284(50):35060-72. PubMed ID: 19837671
[TBL] [Abstract][Full Text] [Related]
25. Expression of HIV-1 Vpu leads to loss of the viral restriction factor CD317/Tetherin from lipid rafts and its enhanced lysosomal degradation.
Rollason R; Dunstan K; Billcliff PG; Bishop P; Gleeson P; Wise H; Digard P; Banting G
PLoS One; 2013; 8(9):e75680. PubMed ID: 24086611
[TBL] [Abstract][Full Text] [Related]
26. A comparative mutational analysis of HIV-1 Vpu subtypes B and C for the identification of determinants required to counteract BST-2/Tetherin and enhance viral egress.
Douglas JL; Bai Y; Gustin JK; Moses AV
Virology; 2013 Jul; 441(2):182-96. PubMed ID: 23582304
[TBL] [Abstract][Full Text] [Related]
27. Vpu is the main determinant for tetraspanin downregulation in HIV-1-infected cells.
Lambelé M; Koppensteiner H; Symeonides M; Roy NH; Chan J; Schindler M; Thali M
J Virol; 2015 Mar; 89(6):3247-55. PubMed ID: 25568205
[TBL] [Abstract][Full Text] [Related]
28. The ESCRT-0 component HRS is required for HIV-1 Vpu-mediated BST-2/tetherin down-regulation.
Janvier K; Pelchen-Matthews A; Renaud JB; Caillet M; Marsh M; Berlioz-Torrent C
PLoS Pathog; 2011 Feb; 7(2):e1001265. PubMed ID: 21304933
[TBL] [Abstract][Full Text] [Related]
29. Vpu downmodulates two distinct targets, tetherin and gibbon ape leukemia virus envelope, through shared features in the Vpu cytoplasmic tail.
Lucas TM; Janaka SK; Stephens EB; Johnson MC
PLoS One; 2012; 7(12):e51741. PubMed ID: 23284757
[TBL] [Abstract][Full Text] [Related]
30. Transmembrane interactions of HIV-1 Vpu and tetherin.
Guo F; Liang C
Curr HIV Res; 2012 Jun; 10(4):292-7. PubMed ID: 22524177
[TBL] [Abstract][Full Text] [Related]
31. β-TrCP is dispensable for Vpu's ability to overcome the CD317/Tetherin-imposed restriction to HIV-1 release.
Tervo HM; Homann S; Ambiel I; Fritz JV; Fackler OT; Keppler OT
Retrovirology; 2011 Feb; 8():9. PubMed ID: 21310048
[TBL] [Abstract][Full Text] [Related]
32. Sites of action of HIV-1 Vpu in BST-2/tetherin downregulation.
Arias JF; Iwabu Y; Tokunaga K
Curr HIV Res; 2012 Jun; 10(4):283-91. PubMed ID: 22524176
[TBL] [Abstract][Full Text] [Related]
33. Efficient Vpu-Mediated Tetherin Antagonism by an HIV-1 Group O Strain.
Mack K; Starz K; Sauter D; Langer S; Bibollet-Ruche F; Learn GH; Stürzel CM; Leoz M; Plantier JC; Geyer M; Hahn BH; Kirchhoff F
J Virol; 2017 Mar; 91(6):. PubMed ID: 28077643
[TBL] [Abstract][Full Text] [Related]
34. Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2.
Jia B; Serra-Moreno R; Neidermyer W; Rahmberg A; Mackey J; Fofana IB; Johnson WE; Westmoreland S; Evans DT
PLoS Pathog; 2009 May; 5(5):e1000429. PubMed ID: 19436700
[TBL] [Abstract][Full Text] [Related]
35. Tetherin restricts direct cell-to-cell infection of HIV-1.
Kuhl BD; Sloan RD; Donahue DA; Bar-Magen T; Liang C; Wainberg MA
Retrovirology; 2010 Dec; 7():115. PubMed ID: 21184674
[TBL] [Abstract][Full Text] [Related]
36. Vpu serine 52 dependent counteraction of tetherin is required for HIV-1 replication in macrophages, but not in ex vivo human lymphoid tissue.
Schindler M; Rajan D; Banning C; Wimmer P; Koppensteiner H; Iwanski A; Specht A; Sauter D; Dobner T; Kirchhoff F
Retrovirology; 2010 Jan; 7():1. PubMed ID: 20078884
[TBL] [Abstract][Full Text] [Related]
37. In vitro functional assessment of natural HIV-1 group M Vpu sequences using a universal priming approach.
Rahimi A; Anmole G; Soto-Nava M; Escamilla-Gomez T; Markle T; Jin SW; Lee GQ; Harrigan PR; Bangsberg DR; Martin J; Avila-Rios S; Reyes-Teran G; Brockman MA; Brumme ZL
J Virol Methods; 2017 Feb; 240():32-41. PubMed ID: 27865749
[TBL] [Abstract][Full Text] [Related]
38. Anti-tetherin activities of HIV-1 Vpu and Ebola virus glycoprotein do not involve removal of tetherin from lipid rafts.
Lopez LA; Yang SJ; Exline CM; Rengarajan S; Haworth KG; Cannon PM
J Virol; 2012 May; 86(10):5467-80. PubMed ID: 22398279
[TBL] [Abstract][Full Text] [Related]
39. HIV-1 Vpu antagonizes BST-2 by interfering mainly with the trafficking of newly synthesized BST-2 to the cell surface.
Dubé M; Paquay C; Roy BB; Bego MG; Mercier J; Cohen EA
Traffic; 2011 Dec; 12(12):1714-29. PubMed ID: 21902775
[TBL] [Abstract][Full Text] [Related]
40. Human-Specific Adaptations in Vpu Conferring Anti-tetherin Activity Are Critical for Efficient Early HIV-1 Replication In Vivo.
Yamada E; Nakaoka S; Klein L; Reith E; Langer S; Hopfensperger K; Iwami S; Schreiber G; Kirchhoff F; Koyanagi Y; Sauter D; Sato K
Cell Host Microbe; 2018 Jan; 23(1):110-120.e7. PubMed ID: 29324226
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
